0.00Open0.88Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover4568.15%IV-5.07%PremiumMay 17, 2024Expiry Date0.66Intrinsic Value100Multiplier-5DDays to Expiry0.22Time Value100Contract SizeAmericanOptions Type-0.5047Delta0.2353Gamma4.93Leverage Ratio-14.9889Theta0.0000Rho-2.49Eff Leverage0.0001Vega
Tenaya Therapeutics Stock Discussion
NEWS
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics is demonstrating continuous innovation in core competencies at the ASGCT 27th Annual Meeting, showcasing its capabilities in genetic medicines for heart disease.
The company's pipeline includes two clinical-stage gene therapies for cardiomyopathies and research on ge...
Furthermore, Tenaya’s second gene therapy product, TN-401, is targeting the treatment of arrhythmogenic right...
Moomoo 24/7· 9 mins ago
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease
Tenaya Anticipates Dosing First ...
No comment yet